CADTH reimbursement recommendation: Emicizumab (Hemlibra) Hoffmann-La Roche Ltd.) : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency)
The CADTH Canadian Plasma Protein Product Expert Committee (CPEC) recommends that emicizumab be reimbursed for the treatment of patients with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
| Edition: | Version 1.0 |
| Series: | CADTH reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Plasma Protein Product Expert Committee (CPEC) recommends that emicizumab be reimbursed for the treatment of patients with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors |
|---|---|
| Physical Description: | 1 PDF file (10 pages) |